Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, estimates its pipeline of so-called new therapeutic entities (NTEs) could generate revenue of $1 billion to $1.5 billion by 2018. This figure could jump to $3 billion in 2020, Elisabeth Kogan, Teva's senior vice president of generic research and development, told reporters on Sunday. NTEs are based on known molecules that are formulated, delivered or used in new ways to address unmet patient needs.